1. Retrospective study of apremilast drug survival in psoriasis patients in a daily practice setting: A long‐term experience.
- Author
-
Galache‐Osuna, Cristina, Reyes‐García, Sebastián, Salgueiro, Esther, Bordallo‐Landa, Javier, Lozano, Ana, Vázquez‐López, Francisco, and Santos‐Juanes, Jorge
- Subjects
- *
APREMILAST , *PROPORTIONAL hazards models , *KAPLAN-Meier estimator , *LOG-rank test , *TERMINATION of treatment - Abstract
There is limited evidence about the real‐world survival of apremilast in patients with psoriasis, especially over the long term. To evaluate the long‐term survival of apremilast and its predictive factors when used to treat psoriasis. A retrospective hospital‐based study, including data collected from 104 patients. Survival curves were estimated using the Kaplan–Meier estimator. Proportional hazard Cox regression models were used for multivariate analysis. The average duration of the treatment before discontinuation was 28.82 months (95% CI, 22.08–35.57 months) and the median was 12 months (95% CI, 2.68–21.31 months). The retention rates were 51% (1 year), and 33% (5 years). The survival study revealed statistically significant differences between patients with PASI<10 and those in the PASI≥10 group (log‐rank test, p < 0.001). The 5‐year prevalences were 64% for patients with a PASI of <10 and 5% for those with an index ≥10. In the PASI < 10‐patient group, the retention rates were 77% (1 year) and 64% (5 years). Furthermore, 66% of patients who continued apremilast treatment for more than 2 years were receiving off‐label doses (30 mg/day). Apremilast may be a suitable and efficient alternative for the treatment of psoriasis patients in the PASI<10 group. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF